Clinical Trials Logo

Eczema clinical trials

View clinical trials related to Eczema.

Filter by:

NCT ID: NCT03676933 Completed - Atopic Dermatitis Clinical Trials

Efficacy and Steroid Sparing Potential Study of DGLA Cream in Early Childhood Patients With Moderate to Severe Atopic Dermatitis

Start date: October 2015
Phase: Phase 2
Study type: Interventional

This study will investigate the steroid sparing potential of DS107E to vehicle in patients with moderate to severe atopic dermatitis. DS107E or vehicle will be topically administered with a steroid twice a day for the first 7 days. For the following 56 days DS107E or vehicle will be topically administered twice a day. This study will enrol approximately 40 paediatric patients.

NCT ID: NCT03676036 Completed - Atopic Dermatitis Clinical Trials

Efficacy and Steroid Sparing Potential Study of DGLA Cream in Patients With Moderate to Severe Atopic Dermatitis

Start date: June 2015
Phase: Phase 2
Study type: Interventional

This study will investigate the steroid sparing potential of DS107E to vehicle in patients with moderate to severe atopic dermatitis. DS107E or vehicle will be topically administered with a steroid twice a day for the first 7 days. For the following 28 days DS107E or vehicle will be topically administered twice a day. This study will enrol approximately 40 adult patients.

NCT ID: NCT03667651 Recruiting - Asthma Clinical Trials

The PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants

PEBBLES
Start date: March 6, 2018
Phase: Phase 3
Study type: Interventional

This is a phase III, single blind (outcome assessor is blinded), randomised controlled multicentre trial of the effect of EpiCeram emollient for improving and maintaining skin barrier function and reducing incidence of eczema and food allergy in high risk infants. A total of 760 participants with a first degree family history of allergic disease (asthma, eczema, allergic rhinitis or food allergy) will be recruited (380 each group) from maternity wards of three hospitals.

NCT ID: NCT03667014 Not yet recruiting - Atopic Dermatitis Clinical Trials

The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

Start date: October 2018
Phase: Phase 4
Study type: Interventional

This is a single-arm, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis patients.

NCT ID: NCT03664271 Not yet recruiting - Eczema Clinical Trials

Educational Eczema Video Intervention

Start date: January 2019
Phase: N/A
Study type: Interventional

The objectives of this study are to increase families' understanding of eczema and improve eczema management in the primary care setting. The investigators plan to create an educational video for families providing general information about eczema as well as instructions about good skincare management and common treatments. The investigators will conduct a randomized controlled trial of the plan in the primary care clinic at Boston Children's Hospital. Specifically, the investigators aim to (1) decrease eczema severity (2) improve patient and family quality of life (QOL) and (3) increase parental knowledge about eczema and eczema management.

NCT ID: NCT03663673 Not yet recruiting - Dermatitis, Atopic Clinical Trials

Comparison of Two Different Skin Creams and Their Effect on Transepidermal Water Loss (TEWL) in Pediatric Patients With Atopic Dermatitis

Start date: September 2018
Phase: Phase 4
Study type: Interventional

Prospective, single center, clinical pilot study to test the hypothesis that lipid rich EpiCeram® is superior in improving skin barrier function compared to Aveeno Daily Moisturising Sheer Hydration Lotion®.

NCT ID: NCT03661866 Not yet recruiting - Psoriasis Clinical Trials

A 5-year Study of Patients Treated for Atopic Dermatitis and Other IMISC

TARGET-DERM
Start date: October 1, 2018
Phase:
Study type: Observational [Patient Registry]

TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

NCT ID: NCT03661138 Not yet recruiting - Atopic Dermatitis Clinical Trials

A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Start date: September 26, 2018
Phase: Phase 3
Study type: Interventional

The objective of this study is to assess the safety of upadacitinib combined with topical corticosteroids (TCS) in adolescent and adult participants in Japan with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

NCT ID: NCT03654755 Not yet recruiting - Atopic Dermatitis Clinical Trials

Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

Start date: September 2018
Phase: Phase 2
Study type: Interventional

This is a randomized open label study to evaluate the long term safety of ASN002 in subjects with moderate to severe atopic dermatitis (AD).

NCT ID: NCT03646604 Not yet recruiting - Atopic Dermatitis Clinical Trials

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects With Severe Atopic Dermatitis

Start date: August 23, 2018
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety, pharmacokinetics and tolerability of multiple doses of upadacitinib in pediatric subjects with severe atopic dermatitis.